Incidence of Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease

References

• Pedersen-Bjergaard J., Larsen S. O. Incidence of acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N. Engl. J. Med. 1982; 307: 965–971
   PubMed Web of Science ®Google Scholar
• Coleman C. N., Williams C. J., Flint A. Hematologic neoplasia in patients treated for Hodgkin's disease. N. Engl. J. Med. 1977; 297: 1249–1252
   PubMed Web of Science ®Google Scholar
• Blayney D. W., Longo D. L., Young R. C. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N. Engl. J. Med. 1987; 316: 710–714
   PubMed Web of Science ®Google Scholar
• Lavey R. S., Eby N. L., Prosnitz L. R. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 1990; 66: 80–88
   PubMed Web of Science ®Google Scholar
• Andrieu J. M., Ifrah N., Payen C. Increased risk of secondary acute nonlymphocytic leukemia after extended field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J. Clin. Oncol. 1990; 8: 1148–1154
   PubMed Web of Science ®Google Scholar
• Koletsky A. J., Bertino J. R., Farber L. R. Second neoplasms in patients with Hodgkin's disease following combined modality therapy. The Yale experience. J. Clin. Oncol. 1986; 4: 311–317
   PubMed Web of Science ®Google Scholar
• Krikorian J. G., Burke J. S., Rosenberg S. A. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N. Engl. J. Med. 1979; 300: 452–458
   PubMed Web of Science ®Google Scholar
• Jacquillat C., Khayat D., Desprez-Curely J. P. Non-Hodgkin's lymphoma occurring after Hodgkin's disease. Four new cases and a review of the literature. Cancer 1984; 53: 459–462
   PubMed Web of Science ®Google Scholar
• Kim H. D., Bedetti C. D., Boggs D. R. The development of non-Hodgkin's lymphoma following therapy for Hodgkin's disease. Cancer 1980; 46: 2596–2602
   PubMed Web of Science ®Google Scholar
• Valagussa P., Santoro A., Fossati-Bellani F. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J. Clin. Oncol. 1986; 4: 830–837
   PubMed Web of Science ®Google Scholar
• Tucker M. A., Coleman C. N., Cox R. S. Risk of second cancers after treatment for Hodgkin's disease. N. Engl. J. Med. 1988; 318: 76–81
   PubMed Web of Science ®Google Scholar
• List A. F., Greer J. P., Cousar J. B. Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein-Barr Virus. Ann. Inter. Med. 1986; 105: 668–673
   PubMed Web of Science ®Google Scholar
• Rijswijk R. E., Verbeek J., Haanen C. Major complications and causes of death in patients treated for Hodgkin's disease. J. Clin. Oncol. 1987; 5: 1624–1633
   PubMed Web of Science ®Google Scholar
• Andrieu J. M., Casassus P., Degos L. Burkitt's lymphoma occurring 6 years after Hodgkin's disease. Acta. Haematol. (Basel) 1980; 63: 330–332
   PubMed Web of Science ®Google Scholar
• Zarrabi M. H., Silberberg J. M., Chandor S. B. Non-Hodgkin's lymphoma following treatment for Hodgkin's disease. Blood 1985; 66: 193a, (Suppl 1)
   Google Scholar
• Epstein M. A., Achong B. G. The relationship of the virus to Burkitt's lymphoma. The Epstein-Barr Virus, M. A. Epstein, B. G. Achong. Springer-Verlag, New York 1979; 321–337
   Google Scholar
• Carbone P. P., Kaplan H. S., Mushoff K. Report of the Committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Lukes R. J., Butler J. J. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966; 26: 1063–1083
   PubMed Web of Science ®Google Scholar
• Longo D. R., Young R. C., Wesley M. Twenty years of MOPP therapy for Hodgkin's disease. J. Clin. Oncol. 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Valagussa P., Santoro A. Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann. Intern. Med. 1986; 104: 739–746
   PubMed Web of Science ®Google Scholar
• Morgenfeld M. C., Pavlovsky A., Suarez A. Combined cyclophosphamide vincristine, procarbazine and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. Cancer 1975; 36: 1241–1249
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's lymphoma pathologic classification group. NCI sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non-parametric stimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Tarone R., Ware J. On distribution-free tests for equality of survival distribution. Biometrika 1977; 64: 154–160
   Web of Science ®Google Scholar
• Kalbfleisch J. D., Prentice R. L. The statistical analysis of failure time data. Wiley, New York 1980
   Google Scholar
• Dixon W. J. Statistical software. University of California. 1987
   Google Scholar
• Arseneau J. C., Canellos G. P., Johnson R. Risk of new cancer in patients with Hodgkin's disease. Cancer 1977; 40: 1912–1916
   PubMed Web of Science ®Google Scholar
• Kersey J. H., Spector B. D., Good R. A. Primary immunodeficiency diseases and cancer. The immunodeficiency cancer registry. Int. J. Cancer 1973; 12: 333–347
   PubMed Web of Science ®Google Scholar
• Blattner W. A., Hoover R. N. Cancer in the immunosuppressed host. Cancer: principles and practice of oncology 2nd ed., V. T. De Vita, Jr., S. Hellman, S. A. Rosemberg. J. B. Lippincott, Philadelphia 1985; 1999–2006
   Google Scholar
• Beral V., Peterman J., Berkelman R. AIDS' associated non-Hodgkin's lymphoma. Lancet 1991; 337: 805–809
   PubMed Web of Science ®Google Scholar
• Editorial. Lymphoma in organ transplant recipients. Lancet 1984; i: 601–603
   Google Scholar
• Penn I. Tumor incidence in human allograft recipients. Transp. Proceed. 1979; 11: 1047–1051
   PubMed Web of Science ®Google Scholar
• Spector B. D., Perry G. S., III, Kersey J. H. Genetically determined immunodeficiency diseases (GDID) and malignancy: a report from the immunodeficiency cancer registry. Clin. Immunol. Immunopathol. 1978; 11: 12–29
   PubMedGoogle Scholar
• Coleman C., Kaplan H. S., Cox R. Leukaemias, non-Hodgkin's lymphomas and solid tumors in patients treated for Hodgkin's disease. Cancer Surv. 1982; 1: 733–744
   Google Scholar
• Kersey J. H., Shapiro R. S., Filipovich A. H. Relationship of immunodeficiency to lymphoid malignancy (1988). Pediatr. Infect. Dis. J. 1985; 7: 10–12, (5 suppl)
   Google Scholar
• Coltman C. A., Dixon D. O. Second malignancies complicating Hodgkin's disease: a Southwest Oncology Group 10-year follow-up. Cancer Treat. Rep. 1982; 66: 1023–1033
   PubMedGoogle Scholar
• List A. F., Greco F. A., Vogler L. B. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr Virus. J. Clin. Oncol. 1987; 5: 1673–1689
   PubMed Web of Science ®Google Scholar